Cointime update: Baili Tianheng’s self-developed Yizekang (iza-bren), the world’s first and only approved EGFR×HER3 bispecific antibody-drug conjugate, was added to China’s 2026 National Reimbursement Drug List following national price negotiations, the list was announced on November 14 at the 2026 National Innovative Drug High-Quality Development Conference. A newly introduced pre-declaration mechanism let the drug enter reimbursement in its first year on the market. The updated list takes effect January 1, 2027.
Baili Tianheng’s Yizekang EGFR×HER3 ADC Added to China’s 2026 National Reimbursement Drug List
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
1h ago
UBS Global Wealth Management Forecasts S&P 500 at 8,200 by End-2027
1h ago
Tencent Q3 2026 Revenue Rises 8% to RMB 207.3 Billion
1h ago
Onshore yuan closes at 6.6653 per dollar, up 2 pips
2h ago
Hong Kong’s Hang Seng closes down 0.91%; Zhipu jumps over 9%
2h ago
Goldman Sachs Forecasts Gold May Return to $5,600 by Late 2028
3h ago
Dollar Holds Near 19-Month High on Fed Rate Hike Expectations